Abstract Library

#4469 Therapeutic strategy for pancreatic neuroendocrine tumours: An overview of the TNE West Network (2016-2024)

Introduction: Neuroendocrine tumours (NETs) are relatively rare and often diagnosed at an advanced stage, typically occurring between the ages of 40 and 60. They primarily manifest in the gastrointestinal system, pancreas, bronchi, lungs, thymus, and thyroid.

Conference:

Presenting Author: Bengueddach A

Authors: Bengueddache A, Kehili H, Tidjane A, Tabeti B, Manouni C,

Keywords: neuroendocrine tumour, metastasis, somatostatin analogue, pancreas,

#4218 Primary hepatic neuroendocrine tumor in a series of 8 cases

Introduction: Primary neuroendocrine (NET) tumors of the liver are extremely rare, accounting for 0.3% of all NETs; unlike metastatic neuroendocrine tumors, rarely cause carcinoid syndrome. Edmonson reported the first case in 1958. Since then, fewer than 150 cases have been reported in the literature. Before making the diagnosis of primary hepatic neuroendocrine tumor it is imperative to explore the patients, several radiological investigations can help to pinpoint the primary which is most often digestive.

Conference:

Presenting Author:

Authors: Samia K, Fatima H, Benali T, Nabil B, Aisha B,

Keywords: neuroendocrine tumor, primary, hepatic, metastasis, rare, neuroendocrin carcinoma,

#3773 Pancreatic neuroendocrine tumors in Oran – Epidemiological, histological and therapeutic aspects

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, they represent third of digestive NETs. Their incidence is increasing with a rate that has been multiplied by 5 over the past 20 years to reach 0.6 cases/100,000. This increase is probably related to better detection of this type of tumor. The discovery is often fortuitous or following a non-specific symptomatology which depends on the seat of the tumor. They are often the cause of mainly hepatic metastases. Only surgery at an early stage allows a good evolution. Few data are available on pNETs in our country.

Conference:

Presenting Author:

Authors: Boumansour N, Khalifa S, Kehili H, Bengueddache A, Tabeti B,

Keywords: pancreas, neuroendocrine tumor, epidemiology, histology,

#3748 Association of MINEN with GIST on neurofibromatosis – A case report

Introduction: Although most digestive neuroendocrine tumors (NETs) are sporadic, around 5% of NETs occur in a context of hereditary predisposition, mainly type 1 multiple endocrine neoplasia (NEM1) and Von Hippel-Lindau disease (VHL).

Conference:

Presenting Author:

Authors: Samia K, Fatima H, Nabil B, Benali T, Aisha B,

Keywords: NEN, GIST, MINEN, DOG1,

#2878 Surgical Management of Neuroendocrine Tumor-Associated Liver Metastases

Introduction: Liver metastasis is common among patients who suffer from neuroendocrine tumors (NETs). Radical surgery is the standard treatment whenever possible but there is still controversies concerning the treatment strategies such as resection of the primary, role of debulking surgery, liver transplantation (LT) and neoadjuvant or adjuvant therapies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bengueddach A, Boudjnene N, Derriche H, Kaid M, Tabeti B,

Keywords: surgery, pancreas, liver metastasis,